Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Syndax Pharmaceuticals Inc - AUGMENT-101 Data Update And KOL Conference Call Transcript

Apr 20, 2021 / 12:00PM GMT
Release Date Price: $13.42 (-30.75%)
Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director

Good morning, and thank you to everyone for joining us on today's call and webcast to review the exciting interim clinical data from AUGMENT-101, our Phase I/II trial of SNDX-5613 in relapsed and refractory acute leukemia. We especially appreciate our colleagues on the West Coast who may have dialed in at this early hour.

Let me start on Slide 2 with our forward-looking statement. We ask that you please reference our SEC documents to see all the various risk factors that come with investing in Syndax.

Slide 3 is our presenter for today. We are very pleased to Dr. Eytan Stein from the Memorial Sloan Kettering Cancer Center, the principal investigator for the AUGMENT-101 trial, who will present our current Phase I data. I will make a few introductory comments, then Eytan will present the data. I will close with a few comments outlining the next steps for 5613, as well as some commentary on the significant market opportunity for the drug. We should have about 15 to 20 minutes for questions.

Turning to Slide 4.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot